Table 4.
Univariate analysis of factors affecting HCC recurrence (after exclusion of 90 days mortality)
| HCC without recurrence (n = 50) | HCC with recurrence (n = 7) | p value | |
|---|---|---|---|
| Age | |||
| Mean ± SD Range |
48.6 ± 6 (40–59) |
52.7 ± 5.1 (47–60) |
0.09 |
| Child score | |||
| A B C |
6 (12 %) 25 (50 %) 19 (38 %) |
2 (28.6 %) 2 (28.6 %) 3 (42.8 %) |
0.43 |
| MELD score | |||
| Mean ± SD Range |
13.9 ± 4.3 (7–20) |
13.9 ± 4.2 (8–19) |
0.99 |
| AFP (ng/mL) (normal <12 ng/mL) | |||
| Mean ± SD Range ≤20 >20, ≤400 >400, <1000 >1000 |
164.5 ± 611.4 (3.4–964) 24 (48 %) 20 (37.8 %) 5 (9.4 %) 0 |
1361.8 ± 1783.2 (3.8–4223) 2 (28.6 %) 0 1 (14.3 %) 4 (57.1 %) |
<
0.01
ᅟ ᅟ ᅟ ᅟ 0.01 |
| Blood transfusion (unit) | |||
| Mean ± SD Range |
5 ± 6 (0–17) |
4 ± 4 (0–10) |
0.81 |
| Pathological tumor grade | |||
| I, II III, IV |
35 (70 %) 15 (30 %) |
3 (42.85 %) 4 (57.15 %) |
0.03 |
| Unilobar Bilobar |
34 (68 %) 16 (32 %) |
3 (42.9 %) 4 (57.1 %) |
0.21 |
| Tumor largest diameter >3 cm | 10 (20 %) | 2 (28.6 %) | 0.63 |
| Microvascular invasion | 4 (8 %) | 4 (57.1 %) | < 0.01 |
| CNI immunosuppressant | 35 (70 %) | 5 (71.4 %) | 1.0 |
| Pathological Milan criteria | |||
| Within Beyond |
37 (74 %) 13 (26 %) |
4 (57.1 %) 3 (42.9 %) |
0.39 |
| Pathological UCSF criteria | |||
| Within Beyond |
40 (80 %) 10 (20 %) |
4 (57.1 %) 3 (42.9 %) |
0.33 |
Statistically significant values are shown in italic
HCC hepatocellular carcinoma, SD standard deviation, HCV hepatitis C virus, HBV hepatitis B virus, MELD model of end-stage liver disease, SD standard deviation, AFP alfa-fetoprotein, ng nanogram, mL milli Leter, UCSF University of California San Francisco criteria, CNI calcineurin inhibitors